BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2022 TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

Published: Jan. 17, 2022 at 7:00 AM CST

MINNEAPOLIS, Jan. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022, at 8:00 a.m. CST to review second quarter fiscal 2022 financial results.

Access to the discussion may be obtained as follows:

Time: 

8:00 a.m. CST

Date: 

February 1, 2022

Dial-in:

1-877-407-9208 or 1-201-493-6784 (for international callers)

Conference ID:

13726340

Webcast: 

https://investors.bio-techne.com/ir-calendar

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13726340.

The replay will be available from 11:00 a.m. CST on Tuesday, February 1, 2022, until 11:00 p.m. CST on Tuesday, March 1, 2022.

*  *  *  *  *  *  *  *  *  *  *  *

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Contact: 
David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

Bio-Techne
Bio-Techne

View original content to download multimedia:

SOURCE Bio-Techne Corporation

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.